Friday, October 23, 2015
08:30-10:00
Hall A
Industry Symposium
Controversies in bone health
Supported by Amgen Oncology
| Chairpersons: | Richard De Boer, Australia Michael Green, Australia |
| 08:30 | The science behind RANK Ligand and its potential impact in breast cancer Geoff Lindeman, Australia |
| 08:50 | Bone targeted agents in metastatic breast cancer: Do bisphosphonates still have a role? Jodi Lynch, Australia |
| 09:10 | Is there a role for radical treatment for isolated or asymptomatic bone metastases? Abe Recht, USA |
| 09:30 | Denosumab: Are hypocalcaemia and ONJ inevitable? Richard de Boer, Australia/ Tracey Huntley, Australia |
| 09:50 | Discussion |
11:30-13:00
Hall A
Industry Symposium
Controversies in HER2-positive disease
Supported by Roche Oncology
| Chairpersons: | Nicole McCarthy, Australia Javier Cortes, Spain |
| 11:30 | How should TILS influence the management of the HER2-positive patient? Sherene Loi, Australia |
| 11:50 | T-DM1 and Pertuzumab: Where do they fit? Javier Cortes, Spain |
| 12:10 | Discussion |
| 12:25-13:00 | Debate: Should all early stage HER2-positive patients receive adjuvant anti-HER therapy? |
| 12:25 | Yes: Edith Perez, USA |
| 12:35 | No: Arlene Chan, Australia |
| 12:45 | Discussion |
Saturday, October 24, 2015
07:00-08:30
Industry Breakfast Symposium
IORT for early breast cancer: From clinical trials to clinical reality
Supported by ZEISS
| Chairperson: | Christobel Saunders, Australia |
| 07:15 | ZEISS INTRABEAM System: A radiotherapy platform, TARGIT study update and new therapy options Robert M. Hermann, Germany |
| 07:30 | General principles of IORT and why we embarked on it Maria Pearse, New Zealand |
| 07:45 | TARGIT Trial results Max Bulsara, Australia |
| 08:00 | Practicalities of setting up IORT Erica Whineray Kelly, New Zealand |
| 08:15 | Discussion |
|
Breakfast will be served prior to the session |
11:30-13:00
Hall A
Industry Symposium
Management of endocrine resistance
Supported by Novartis Oncology
| Chairpersons: | Richard De Boer, Australia Louis Chow, Hong Kong |
| 11:30 | Endocrine resistance: The science behind the studies Stephen R.D. Johnston, UK |
| 11:50 | Current strategies: Their advantages and practical limitations - Patient selection - Toxicity management Arlene Chan, Australia |
| 12:10-13:00 | Debate: Targeted therapies and endocrine treatments should be combined upfront before endocrine resistance can develop |
| 12:10 | Yes: Javier Cortes, Spain |
| 12:20 | No: Stephen R.D. Johnston, UK |
| 12:30 | Discussion |